Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concomitant Use of Pneumococcal Vaccines and mRNA-1273 in Adults 50+
NCT05158140Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2022
- Primary completion
- Feb 2023
- Modality
- Split/Subunit Vaccines
- Countries
- 2
01
Overview
A Phase 3 trial of 23-valent pneumococcal polysaccharide vaccine, pneumococcal 15-valent conjugate vaccine in pneumococcal disease, coronavirus disease 2019 (COVID-19), sponsored by Merck & Co.. Started Jan 2022; status: completed.
02
Drugs
23-valent pneumococcal polysaccharide vaccinepneumococcal 15-valent conjugate vaccine
03
Conditions
pneumococcal diseasecoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05158140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05158140.